[HTML][HTML] Clinical management of epidermal growth factor receptor mutation-positive non-small cell lung cancer patients after progression on previous epidermal …
JL González-Larriba, M Lázaro-Quintela… - Translational Lung …, 2017 - ncbi.nlm.nih.gov
One of the most important advances in the treatment of non-small cell lung cancer (NSCLC)
has been the identification of molecular alterations vulnerable to targeted inhibition, such as …
has been the identification of molecular alterations vulnerable to targeted inhibition, such as …
Advanced non-small-cell lung cancer with epidermal growth factor receptor mutations: current evidence and future perspectives
R Costanzo, A Montanino, M Di Maio… - Expert Review of …, 2013 - Taylor & Francis
The identification of activating mutations in the tyrosine kinase domain of the EGF receptor
(EGFR) predictive of response to tyrosine kinase inhibitors (TKIs) led to a therapeutic …
(EGFR) predictive of response to tyrosine kinase inhibitors (TKIs) led to a therapeutic …
A Real-World, Observational, Prospective Study to Assess the Molecular Epidemiology of Epidermal Growth Factor Receptor (EGFR) Mutations upon Progression on or after …
G Mountzios, A Koumarianou, A Bokas, D Mavroudis… - Cancers, 2021 - mdpi.com
Simple Summary Non-small cell lung cancer (NSCLC) accounts for approximately 85% of
lung cancer cases, with few patients carrying driver mutations in the gene encoding for …
lung cancer cases, with few patients carrying driver mutations in the gene encoding for …
EGFR mutations: Best results from second-and third-generation tyrosine kinase inhibitors
A Manzo, A Montanino, R Costanzo, C Sandomenico… - Oncogenomics, 2019 - Elsevier
In the past few years, the discovery of epidermal growth factor receptor (EGFR) activating
mutations and the demonstration of efficacy of EGFR tyrosine kinase inhibitors (TKIs) have …
mutations and the demonstration of efficacy of EGFR tyrosine kinase inhibitors (TKIs) have …
Generations of epidermal growth factor receptor tyrosine kinase inhibitors: perils and progress
EH Castellanos, L Horn - Current treatment options in oncology, 2015 - Springer
Opinion statement Epidermal growth factor receptor (EGFR) mutations have been detected
in approximately 10% of North American patients diagnosed with non-small cell lung cancer …
in approximately 10% of North American patients diagnosed with non-small cell lung cancer …
Distinct Clinical Outcomes of Non-Small Cell Lung Cancer Patients with Epidermal Growth Factor Receptor (EGFR) Mutations Treated with EGFR Tyrosine Kinase …
SH Hsiao, HE Liu, HL Lee, CL Lin, WY Chen, ZH Wu… - PLoS …, 2013 - journals.plos.org
Introduction Treatment with epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors (TKIs) has been associated with favorable progression free survival (PFS) in …
inhibitors (TKIs) has been associated with favorable progression free survival (PFS) in …
Therapeutic strategy for advanced EGFR mutant non-small-cell lung carcinoma
J Cadranel, AM Ruppert, M Beau-Faller… - Critical reviews in …, 2013 - Elsevier
Activating mutation in exons 19 or 21 of epidermal growth factor receptor (EGFR) in non-
small-cell lung cancers (NSCLC) are associated with increased sensitivity to EGFR tyrosine …
small-cell lung cancers (NSCLC) are associated with increased sensitivity to EGFR tyrosine …
First-line treatment for advanced nonsmall cell lung cancer harboring activating epidermal growth factor receptor mutation: epidermal growth factor receptor tyrosine …
C Gridelli - Current Opinion in Oncology, 2011 - journals.lww.com
In advanced nonsmall cell lung cancer (NSCLC), the epidermal growth factor receptor
(EGFR) is a major therapeutic target. Activating EGFR mutations, including either an in …
(EGFR) is a major therapeutic target. Activating EGFR mutations, including either an in …
Tyrosine kinase inhibitors for epidermal growth factor receptor gene mutation–positive non-small cell lung cancers: an update for recent advances in therapeutics
C Chung - Journal of Oncology Pharmacy Practice, 2016 - journals.sagepub.com
The presence of activating gene mutations in the epidermal growth factor receptor of non-
small cell lung cancer patients is predictive (improved progression-free survival and …
small cell lung cancer patients is predictive (improved progression-free survival and …
[HTML][HTML] Biopsy on progression in patients with EGFR mutation–positive advanced non-small-cell lung cancer—a Canadian experience
Q Chu, A Agha, N Devost, RN Walton… - Current …, 2020 - pmc.ncbi.nlm.nih.gov
Background Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors (tki s) are
standard therapy for patients with advanced or metastatic non-small-cell lung cancer …
standard therapy for patients with advanced or metastatic non-small-cell lung cancer …